News
SVRA
--
0.00%
--
Checkpoint Therapeutics, Nano-X Imaging leads healthcare gainers, Evofem Biosciences, Satsuma Pharmaceuticals among major losers
Gainers: Checkpoint Therapeutics (CKPT) +29%, Nano-X Imaging (NNOX) +21%, Biofrontera AG (BFRA) +20%, Zymeworks (ZYME) +14%, MEI Pharma (MEIP) +12%.Losers: Evofem Biosciences (EVFM) -20%, Satsuma Pharmaceuticals (STSA) -11%, Corbus Pharmaceuticals Holdings (CRBP) -10%, Savara (SVRA) -9%, BiondVax Pharmaceuticals (BVXV) -8%.
Seekingalpha · 09/11 15:05
Savara plummets 11% premarket; appoints interim CEO
Savara (SVRA) down 11% premarket. CEO Rob Neville is moving on from his role and as a board member; Matthew Paul, has been appointed as Chairman and the interim.Taneli Jouhikainen, President and Chief Business Officer,
Seekingalpha · 09/11 13:29
Savara Announces Senior Management Changes
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that Rob Neville has resigned as the Company’s Chief Executive Officer (CEO) and from the Board of Directors, effective immediately, to pursue other opportunities. The Company’s Board of Directors has appointed Matthew Pauls
Business Wire · 09/11 13:05
Savara to Present at the 22nd Annual H.C. Wainwright Annual Investment Conference Being Held Virtually
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that Savara management will be presenting at the H.C. Wainwright Annual Investment Conference on Wednesday, September 16, 2020 at 3:00 PM EDT/12:00 PM PDT.
Business Wire · 09/09 20:05
Savara Announces New England Journal of Medicine (NEJM) Publication of IMPALA Study Results
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that results from the Phase 3 IMPALA study were published online in NEJM. The manuscript, titled "Inhaled Molgramostim Therapy in Autoimmune Pulmonary Alveolar Proteinosis," appears in the September 7, 2020 online version
Business Wire · 09/08 13:05
Akebia Anemia Data, And Other News: The Good, Bad And Ugly Of Biopharma
Akebia reports data for its anemia drug candidate.Abbott moves ahead with Drug-Eluting resorbable scaffold.Savara announces discontinuing Molgradex for NTM lung infection.
Seekingalpha · 09/07 03:16
The Daily Biotech Pulse: AbbVie In-licenses I-Mab's Cancer Drug, Savara Pulls The Plug On Cystic Fibrosis Study
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 3)
Benzinga · 09/04 11:28
Savara to Discontinue Exploratory ENCORE Study Evaluating Molgradex for the Treatment of NTM Lung Infection in People Living With Cystic Fibrosis (CF)
Business Wire · 09/03 20:05
Savara Enters Oversold Territory
Savara has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Zacks · 08/25 12:42
Savara Reports Second Quarter 2020 Financial Results and Provides Business Update
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today reported financial results for the second quarter ending June 30, 2020 and provided a business update.
Business Wire · 08/06 20:02
Savara to Present at the 40th Annual Canaccord Genuity Global Growth Conference to be Held Virtually
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that the Company's Chief Executive Officer, Rob Neville, will present at the virtual Canaccord Genuity Global Growth Conference on Wednesday, August 12, 2020 at 8:00 a.m. Eastern Time
Business Wire · 08/05 12:05
Savara to Report Second Quarter 2020 Financial Results and Provide Business Update
Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced that the Company will report second quarter 2020 financial results and provide a business update on Thursday, August 6, 2020. Savara management will host a conference call/webcast at 4
Business Wire · 07/30 12:05
Were Hedge Funds Right About Souring On Savara, Inc. (SVRA)?
Insider Monkey · 07/05 23:11
Savara to Present at the Jefferies Virtual Healthcare Conference
Business Wire · 05/27 21:05
Savara Announces Change of Date for 2020 Annual Meeting of Stockholders
Business Wire · 05/08 13:05
Savara Inc. (SVRA) CEO Rob Neville on Q1 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 05/07 22:52
Savara Reports First Quarter 2020 Financial Results and Provides Business Update
Business Wire · 05/07 21:05
Savara Q1 EPS $(0.270) Up From $(0.340) YoY
Savara (NASDAQ:SVRA) reported quarterly losses of $(0.270) per share. This is a 20.59 percent increase over losses of $(0.340) per share from the same period last year.
Benzinga · 05/07 20:12
Savara to Report First Quarter 2020 Financial Results and Provide Business Update
Business Wire · 04/30 21:05
Are Insiders Buying Savara Inc. (NASDAQ:SVRA) Stock?
Simply Wall St. · 04/15 16:26
Webull provides a variety of real-time SVRA stock news. You can receive the latest news about Savara through multiple platforms. This information may help you make smarter investment decisions.
About SVRA
Savara Inc., formerly Mast Therapeutics, Inc., is an orphan lung disease company. The Company is engaged in the development and commercialization of novel therapeutics to address unmet medical needs. Its product pipeline include Molgradex, AeroVanc and Aironite. Molgradex is an inhaled formulation of recombinant human GM-CSF. It is developing Molgradex for the treatment of pulmonary alveolar proteinosis (PAP) and nontuberculous mycobacterial (NTM) lung infection. AeroVanc is a vancomycin hydrochloride inhalation powder. It is developing AeroVanc as an antibiotic for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) lung infection in individuals living with cystic fibrosis (CF). Aironite is a sodium nitrite inhalation solution. Aironite is an investigational product. The Company is developing Molgradex in a pivotal Phase-III clinical trial for the treatment of PAP and in a Phase II a study for NTM lung infection. AeroVanc is in a Phase-III clinical trial.
More